Q-omics provides the consensus-scored GPR15 profile across patient tissues and cancer cell-line models. GPR15 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GPR15 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, GPR15 RNA expression shows 12,659 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where GPR15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR15 survival associations across molecular data types. GPR15 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR15 RNA expression–survival associations across cancer types. High GPR15 expression shows unfavorable associations in UVM, LGG and STAD, but favorable associations in HNSC, LUAD and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GPR15 RNA expression.
This table summarizes GPR15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GPR15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR15 shows lower tumor expression in COAD, HNSC, BRCA, READ and BLCA and higher tumor expression in KIRC. The COAD box plot shows higher GPR15 RNA expression in normal versus tumor tissue (log2 FC = −4.004, t-test p < 0.001).
This table shows molecular features associated with GPR15 in patient tissues and cancer cell lines. In patient samples, GPR15 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
